Yue Zhou

Nanjing Medical University

H指数:17

被引数:1,281

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRIM46 drives lung adenocarcinoma progression by stabilizing PRDX1 via SUMOylation

TRIM46通过SUMO化稳定PRDX1来驱动肺腺癌进展

Cell Death & Disease

IF9.6

2026-09-220

OAAI

MMP9 Serves as a Prognostic Biomarker and Immune-Associated Regulator in Diffuse Large B-Cell Lymphoma

MMP9作为弥漫性大B细胞淋巴瘤的预后生物标志物和免疫相关调节因子

Cell Biochemistry and Function

IF2.7

2026-04-140

PRE

Correction: TAB182 aggravates progression of esophageal squamous cell carcinoma by enhancing β-catenin nuclear translocation through FHL2 dependent manner

更正：TAB182 通过 FHL2 依赖性方式增强 β-catenin 核转位，从而加剧食管鳞状细胞癌的进展。

Cell Death & Disease

IF9.6

2025-12-230

OAAI

Utilizing multimodal models to forecast Alzheimer's disease progression and clinical subtypes

利用多模态模型预测阿尔茨海默病的进展和临床亚型

Health Information Science and Systems

IF3.4

2025-12-080

Evaluating the risk of osteopenia-related adverse events with antiepileptic drugs: a pharmacovigilance study based on the FAERS database

评估抗癫痫药物相关骨量减少不良事件的风险：一项基于FAERS数据库的药物警戒研究

Frontiers in Pharmacology

IF4.8

2025-10-130

OAAI

Synthesis of lanthanum-based porous magnetic ceramsite for the treatment of excessive phosphorus of water

用于处理水中过量磷的镧基多孔磁性陶粒的合成

Journal of Industrial and Engineering Chemistry

IF6

2025-09-240

PRE

Biomimetic peptides in bone tissue engineering: From function to application

仿生肽在骨组织工程中的应用：从功能到应用

colloids and surfaces b biointerfaces

IF0

2025-08-070

PRE

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

奥法木单抗的真实世界安全性：基于美国食品药品监督管理局不良事件报告系统的药物警戒分析

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-01-230

OAAI

Selenium-Doped Copper Formate Nanozymes with Antisenescence and Oxidative Stress Reduction for Atherosclerosis Treatment

硒掺杂甲酸铜纳米酶，具有抗衰老和减轻氧化应激作用，用于动脉粥样硬化治疗

NANO LETTERS

IF9.1

2025-01-171

PRE

Tumor microenvironment-responsive hyperbranched polymers for controlled drug delivery

肿瘤微环境响应性超支化聚合物用于药物控释

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2024-12-010

OAAI

Artemisinin attenuates perinatal inflammation and consequent oxidative stress in oligodendrocyte precursor cells by inhibiting IRAK-4 and IRAK-1

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2024-12-010

OAAI

Cathepsin B modulates microglial migration and phagocytosis of amyloid β in Alzheimer's disease through PI3K-Akt signaling

NEUROPSYCHOPHARMACOLOGY

IF7.1

2024-09-200

PRE

Direct detection of acetylcholinesterase by Fe(HCOO)2.6(OH)0.3. H2O nanosheets with oxidase-like activity on a smartphone platform

TALANTA

IF6.1

2024-07-010

PRE

Three-dimensional porous chitosan gel microspheres loaded with Ni and La for the treatment of inorganic and organic phosphorus in the water environment

JOURNAL OF WATER PROCESS ENGINEERING

IF6.7

2024-06-010

PRE

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical bene fi t, 2001 - 2020

LANCET REGIONAL HEALTH-WESTERN PACIFIC

IF8.1

2024-04-010

OAAI

DNA polymerase iota promotes EMT and metastasis of esophageal squamous cell carcinoma by interacting with USP7 to stabilize HIF-1α

CELL DEATH & DISEASE

IF9.6

2024-02-243

OAAI

H-Bond Modulation Mechanism for Moisture-driven Bacteriostat Evolved from Phytochemical Formulation

ADVANCED FUNCTIONAL MATERIALS

IF19

2023-12-214

PRE

Copper formate-lysine nanoparticles with polyphenol oxidase-like activity for the detection of epinephrine

ANALYTICAL AND BIOANALYTICAL CHEMISTRY

IF3.8

2023-12-121

PRE

Longan pulp polysaccharides regulate gut microbiota and metabolites to protect intestinal epithelial barrier

FOOD CHEMISTRY

IF9.8

2023-10-0118

PRE

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021

BMJ GLOBAL HEALTH

IF6.1

2023-09-281

OAAI

Yue Zhou

个人简介

教育背景

工作经历

荣誉奖项

研究方向